Axonics, Inc. - AXNX STOCK NEWS

Axonics reported record quarterly revenue of $70 million, marking a 50% increase year-over-year. The company raised its fiscal year 2022 revenue guidance to $262 million, up 45% from the previous year. Sacral neuromodulation revenue reached $56.9 million, driven by the successful launch of the Axonics F15™ system. Gross margin improved to 72.8% from 66.5%. Though operating expenses rose to $67.6 million, the net loss narrowed to $16.3 million from $17.3 million in the prior year. Cash reserves stood at $350 million as of September 30, 2022.

Axonics (NASDAQ: AXNX), a medical technology firm, will announce its Q3 2022 financial results after market close on October 31. A conference call will be held at 4:30 p.m. ET to discuss the results. Interested participants can register in advance via a provided link. The company specializes in products for bladder and bowel dysfunction and has recently achieved notable rankings in growth metrics.

Axonics, Inc. (NASDAQ: AXNX) announced the first Canadian implants of its Axonics F15™ sacral neuromodulation system, which offers a long-lived, fully recharge-free solution for bladder and bowel dysfunction. The University of Alberta performed the procedures on four patients, expecting battery longevity of 18 to 22 years. This follows previous FDA and Health Canada approvals. The Axonics F15 aims to enhance adoption of sacral neuromodulation therapy, significantly improving quality of life for millions suffering from incontinence in North America.

Axonics, Inc. (NASDAQ: AXNX), headquartered in Irvine, California, has announced its participation in key investor conferences. Senior management will present at the Wells Fargo Healthcare Conference on September 8, 2022 at 10:25 a.m. ET, followed by the Morgan Stanley Healthcare Conference on September 12, 2022 at 11:05 a.m. ET. Interested investors can access the live and archived webcasts on the Axonics investor relations website.

Axonics, Inc. (NASDAQ: AXNX) has announced the granting of eight patents and the allowance of four patent applications related to its sacral neuromodulation technology over the past year. These patents cover innovations such as the Axonics external trial system and implantable neurostimulator. CEO Raymond W. Cohen emphasized the company’s commitment to addressing the needs of adults with incontinence. Axonics' product portfolio includes clinically proven therapies for overactive bladder and fecal incontinence, with established reimbursement coverage in the U.S. and Europe.

Axonics, Inc. (NASDAQ: AXNX) has successfully closed its public offering of 2,012,500 shares of common stock at $63.85 per share, with gross proceeds of approximately $128.5 million. The offering included the full exercise of the underwriter's option to purchase an additional 262,500 shares. BofA Securities acted as the sole book-running manager for this offering, which was conducted under an existing shelf registration statement filed with the SEC. Axonics specializes in innovative treatments for bladder and bowel dysfunction.

Axonics, Inc. (NASDAQ: AXNX) has announced the pricing of its underwritten public offering of 1,750,000 shares of common stock, set to close on August 5, 2022. The underwriter has a 30-day option to purchase an additional 262,500 shares. The net proceeds will be used for working capital and general corporate purposes, which may include a potential $35 million milestone payment related to the acquisition of Contura Limited. BofA Securities is the sole book-running manager for this offering.

Axonics, a medical technology company focused on bladder and bowel dysfunction, has initiated a proposed underwritten public offering of 1,750,000 shares of its common stock, with an option for underwriters to purchase an additional 262,500 shares. The proceeds will support working capital and may include a $35 million milestone payment related to its acquisition of Contura Limited. BofA Securities is the sole book-running manager for the offering, which is subject to market conditions. The shares are offered under a previously filed registration statement with the SEC.

Axonics, Inc. reported record quarterly revenue of $69 million for 2Q22, marking a 50% year-over-year increase. Fiscal year 2022 revenue guidance has been revised upward to $253 million, a 40% increase compared to 2021. Sacral neuromodulation revenue soared by 39%, driven by the broad launch of the Axonics F15™ system. Bulkamid® also achieved record sales, projecting treatment for 50,000 women in 2022. Gross margin improved to 72.8%, though operating expenses rose, leading to a net loss of $21.4 million this quarter.